{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:47:25Z","timestamp":1794944845903,"version":"4.9.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"32","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100005971","name":"the German Heart Foundation","doi-asserted-by":"publisher","award":["S\/06\/23"],"award-info":[{"award-number":["S\/06\/23"]}],"id":[{"id":"10.13039\/501100005971","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Elevated LDL-cholesterol levels and inflammation, as assessed by high-sensitivity C-reactive protein, correlate with cardiovascular risk. However, data on the relative impact of residual LDL-cholesterol and inflammatory risk among statin-treated patients undergoing percutaneous coronary intervention (PCI) is lacking. Hence, this study aimed to investigate the impact of residual cholesterol\/inflammatory risk in patients on statin therapy undergoing PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From 2012 to 2022, patients at a tertiary centre undergoing PCI were analysed. Patients were stratified according to LDL-cholesterol (\u226570 vs &amp;lt;70 mg\/dL) and high-sensitivity C-reactive protein (\u22652 vs &amp;lt;2 mg\/L) levels: no residual cholesterol or inflammatory risk, residual cholesterol risk, residual inflammatory risk, and combined residual cholesterol and inflammatory risk. Patients presenting with acute myocardial infarction, cancer, no statin treatment at admission, or high-sensitivity C-reactive protein levels &amp;gt;10 mg\/L were excluded. The primary endpoint was major adverse cardiovascular events (MACEs), defined as the composite of all-cause mortality, spontaneous myocardial infarction, and stroke 1 year after the index PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 15 494 patients were included. After 1-year follow-up, individuals with isolated residual inflammatory risk had the highest MACE rate (5.1%), followed by patients with combined cholesterol and inflammatory risk, no residual risk, and isolated residual cholesterol risk. After multivariable Cox regression analysis, patients with residual inflammatory risk had a 1.8-fold higher risk for MACE (adjusted hazard ratio: 1.78, 95% confidence interval 1.36\u20132.33, P &amp;lt; .001) compared with those with no residual cholesterol or inflammatory risk. This was similar in patients with combined residual cholesterol and inflammatory risk (adjusted hazard ratio: 1.56, 95% confidence interval 1.19\u20132.04, P = 0.001). Of note, no independent association of isolated residual cholesterol risk (adjusted hazard ratio: 1.01, 95% confidence interval .76\u20131.35, P-value = .920) with MACE was noted (P-trend across all groups &amp;lt;.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among statin-treated patients undergoing PCI, residual inflammation but not cholesterol risk was associated with an increased risk of MACE during follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf196","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:15:05Z","timestamp":1742170505000},"page":"3167-3177","source":"Crossref","is-referenced-by-count":71,"title":["Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4927-8033","authenticated-orcid":false,"given":"Benjamin","family":"Bay","sequence":"first","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]},{"name":"Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Tanner","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]},{"name":"Department of Cardiology, Cork University Hospital , Cork ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gao","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Oliva","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-9409","authenticated-orcid":false,"given":"Samantha","family":"Sartori","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9896-403X","authenticated-orcid":false,"given":"Birgit","family":"Vogel","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Gitto","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth F","family":"Smith","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Di Muro","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]},{"name":"Structural Interventional Cardiology Division, Department of Cardiac Thoracic and Vascular Medicine, Azienda Ospedaliero-Universitaria Careggi , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Hooda","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sweeny","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parasuram","family":"Krishnamoorthy","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moreno","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dangas","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annapoorna","family":"Kini","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1888-0793","authenticated-orcid":false,"given":"Samin K","family":"Sharma","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"2025101322573836400_ehaf196-B1","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"key":"2025101322573836400_ehaf196-B2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025101322573836400_ehaf196-B3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"2025101322573836400_ehaf196-B4","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2025101322573836400_ehaf196-B5","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1161\/CIRCULATIONAHA.118.035289","article-title":"Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine","volume":"137","author":"Patel","year":"2018","journal-title":"Circulation"},{"key":"2025101322573836400_ehaf196-B6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2025101322573836400_ehaf196-B7","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2025101322573836400_ehaf196-B8","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2025101322573836400_ehaf196-B9","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"2025101322573836400_ehaf196-B10","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"2025101322573836400_ehaf196-B11","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1016\/j.jacc.2020.03.070","article-title":"Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients","volume":"75","author":"Cao","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025101322573836400_ehaf196-B12","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2025101322573836400_ehaf196-B13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","article-title":"Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis","volume":"3","author":"Sabatine","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2025101322573836400_ehaf196-B14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2025101322573836400_ehaf196-B15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","volume":"42","author":"Lawler","year":"2021","journal-title":"Eur Heart J"},{"key":"2025101322573836400_ehaf196-B16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","article-title":"Inflammatory and cholesterol risk in the FOURIER trial","volume":"138","author":"Bohula","year":"2018","journal-title":"Circulation"},{"key":"2025101322573836400_ehaf196-B17","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"2025101322573836400_ehaf196-B18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2025101322573836400_ehaf196-B19","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"2025101322573836400_ehaf196-B20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance","volume":"149","author":"Ridker","year":"2024","journal-title":"Circulation"},{"key":"2025101322573836400_ehaf196-B21","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"2025101322573836400_ehaf196-B22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jacl.2023.02.002","article-title":"Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: a secondary analysis of the CLEAR harmony trial","volume":"17","author":"Ridker","year":"2023","journal-title":"J Clin Lipidol"},{"key":"2025101322573836400_ehaf196-B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2023.03.020","article-title":"Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: analysis of pooled data from four phase 3 clinical trials","volume":"373","author":"Stroes","year":"2023","journal-title":"Atherosclerosis"},{"key":"2025101322573836400_ehaf196-B24","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.4244\/EIJ-D-20-00999","article-title":"Lipid-lowering therapy and percutaneous coronary interventions","volume":"16","author":"Koskinas","year":"2021","journal-title":"EuroIntervention"},{"key":"2025101322573836400_ehaf196-B25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly","year":"2024","journal-title":"N Engl J Med"},{"key":"2025101322573836400_ehaf196-B26","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2025101322573836400_ehaf196-B27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.121.056171","article-title":"Colchicine in cardiovascular disease: in-depth review","volume":"145","author":"Deftereos","year":"2022","journal-title":"Circulation"},{"key":"2025101322573836400_ehaf196-B28","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.119.045256","article-title":"From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents?","volume":"141","author":"Ridker","year":"2020","journal-title":"Circulation"},{"key":"2025101322573836400_ehaf196-B29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/01.cir.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"2025101322573836400_ehaf196-B30","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jacc.2019.11.058","article-title":"Stent-related adverse events &gt;1 year after percutaneous coronary intervention","volume":"75","author":"Madhavan","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025101322573836400_ehaf196-B31","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1093\/eurheartj\/ehy223","article-title":"Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document","volume":"39","author":"Garcia-Garcia","year":"2018","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/32\/3167\/62904590\/ehaf196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/32\/3167\/62904590\/ehaf196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T02:58:47Z","timestamp":1760410727000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/32\/3167\/8110175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":31,"journal-issue":{"issue":"32","published-online":{"date-parts":[[2025,4,10]]},"published-print":{"date-parts":[[2025,8,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf196","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,21]]},"published":{"date-parts":[[2025,4,10]]}}}